Brief: Beam Therapeutics Reports Progress Across Base Editing Portfolio

Beam Therapeutics

09/01/2023 12:23

Jan 9 (Reuters) - Beam Therapeutics Inc  BEAM.O :
    * BEAM THERAPEUTICS REPORTS PROGRESS ACROSS BASE EDITING
PORTFOLIO
AND OUTLINES KEY ANTICIPATED MILESTONES
    * BEAM THERAPEUTICS INC - BEACON TRIAL OF BEAM-101 IN SICKLE
CELL
DISEASE ONGOING WITH DATA FROM MULTIPLE PATIENTS EXPECTED IN
2024
    * BEAM THERAPEUTICS INC - FIRST PATIENT DOSING IN BEAM-201
TRIAL
IN PATIENTS WITH T-ALL/T-LL EXPECTED BY MID-2023
    * BEAM THERAPEUTICS INC - REGULATORY SUBMISSIONS PLANNED FOR
BEAM-301 BY LATE 2023/EARLY 2024 AND BEAM-302 IN EARLY 2024
    * BEAM THERAPEUTICS INC - NORTH CAROLINA MANUFACTURING
FACILITY
EXPECTED TO INITIATE GMP OPERATIONS IN LATE 2023
    * BEAM THERAPEUTICS INC - ABOUT $1 BILLION ESTIMATED CASH,
CASH
EQUIVALENTS AND MARKETABLE SECURITIES AT YEAR-END 2022; CASH
RUNWAY EXPECTED INTO 2025

Source text for Eikon:  ID:nGNX8k63K2 
Further company coverage:  BEAM.O 
 ((Reuters.Briefs@thomsonreuters.com;))